Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics Inc (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company advancing novel therapies for dermatological conditions, oncology targets, and neurodegenerative disorders. This news hub provides investors and researchers with timely updates on clinical trial progress, regulatory milestones, and strategic partnerships central to evaluating Hoth’s therapeutic pipeline.
Discover authoritative coverage of Hoth’s innovative platforms including the BioLexa antimicrobial system and HT-ALZ for Alzheimer’s research. Our curated news collection features press releases on FDA designations, preclinical data disclosures, and licensing agreements with academic institutions like George Washington University and North Carolina State University.
Key updates include developments across three core areas: dermatology (eczema/chronic wound treatments), oncology (HT-KIT for mast cell cancers), and neurology (neuroinflammation targeting). Each news item is verified for accuracy to support informed analysis of Hoth’s research trajectory and market position.
Bookmark this page for consolidated access to Hoth Therapeutics’ latest announcements, including earnings reports, intellectual property filings, and collaborative research initiatives. Regularly updated to serve as your primary resource for tracking this innovative biopharma’s progress in addressing unmet medical needs.
Hoth Therapeutics (NASDAQ: HOTH) announced breakthrough interim results for its HT-001 Phase 2a clinical trial, achieving a 100% response rate in at least one primary endpoint for treating EGFR inhibitor-induced skin toxicities. The trial demonstrated that over 65% of patients reported reduced pain and itching, with no patients requiring dose reduction or discontinuation of their cancer treatment.
HT-001, a once-daily topical gel containing an FDA-approved NK1 receptor antagonist, targets inflammatory pathways triggered by EGFR inhibition. The therapy showed significant efficacy in preclinical studies and is being developed under the 505(b)(2) regulatory pathway, positioning it to potentially become the first FDA-approved treatment specifically for EGFRI-related skin toxicities, which affect up to 90% of cancer patients receiving EGFR inhibitors.
Hoth Therapeutics (NASDAQ: HOTH) has announced positive preclinical results for HT-KIT, its antisense oligonucleotide therapy targeting KIT-driven cancers. The treatment demonstrated over 80% reduction in KIT expression in vitro and significant tumor growth inhibition in gastrointestinal stromal tumors (GIST) and mast cell tumor models.
Key achievements include successful targeting of mutant KIT mRNA transcripts with no observable off-target toxicity in liver, kidney, or bone marrow. The company plans to file an Investigational New Drug (IND) application with the FDA in early 2026, followed by Phase 1 trials. HT-KIT represents a potential alternative to current tyrosine kinase inhibitors (TKIs), addressing drug resistance concerns through its mRNA-level targeting approach.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
